Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia

  title={Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia},
  author={Phy Ho and Robert C. Baxter},
  journal={Clinical Endocrinology},
  • P. Ho, R. Baxter
  • Published 1 February 1997
  • Medicine, Biology
  • Clinical Endocrinology
OBJECTIVE Insulin‐like growth factor‐binding protein (IGFBP)‐2 is a major prostatic IGFBP and may be involved in regulating prostate growth. Patients with prostate carcinoma (PC) have elevated serum IGFBP‐2 levels which correlate with the specific PC marker, prostate‐specific antigen (PSA). The aims of this study were to investigate whether elevated serum IGFBP‐2 is unique to PC or also occurs in benign prostatic hyperplasia (BPH), to examine the relations among age, PSA and IGFBP‐2 levels, and… 
Increased levels of insulin‐like growth factor binding protein‐2 in sera and tumours from patients with colonic neoplasia with and without acromegaly
OBJECTIVE Patients with acromegaly are at increased risk of developing colorectal carcinoma and premalignant tubulovillous adenoma. The pathogenesis of these neoplasms could involve a stimulatory
Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
In screen-positive men with elevated serum PSA, serum IGF-I is not a useful diagnostic test for prostate cancer, but it may be associated with benign prostatic hyperplasia and enlargement.
Prostatic fluid‐free insulin‐like growth factor‐1 in relation to prostate cancer
Objectives To establish the feasibility of measuring free insulin‐like growth factor‐1 (IGF‐1) in prostatic fluid and to determine if there is a difference in free IGF‐1 levels in the prostatic fluid
Role of insulin‐like growth factors and their binding proteins in growth control and carcinogenesis
Perturbations in each level of the IGF axis have been implicated in cancer formation and progression in various cell types and are believed to occur through IGFBP‐3‐specific cell surface association proteins or receptors and involves nuclear translocation.
Serum insulin‐like growth factor‐1 is not a useful marker of prostate cancer
To determine whether the use of serum insulin‐like growth factor 1 (IGF‐1) levels is more efficient than serum prostate specific antigen (PSA) levels in predicting prostate cancer in patients undergoing prostatic biopsy, a comparison study is conducted on animals and humans.
Pilot Study of Elevated Levels of Insulin-Like Growth Factor-Binding Protein-2 as Indicators of Hepatocellular Carcinoma
In addition to AFP, IGFBP-2 appears to be a suitable marker for the evaluation of the serological status of HCC patients, as is the case when nutrition, hepatic function and growth hormone (GH) secretion are decreased.
High expression of insulin‐like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels
  • J. Lancaster, R. Sayer, A. Berchuck
  • Biology, Medicine
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2006
The findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis and that IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithel ovarian cancer.
Elevated Serum Insulin-Like Growth Factor Binding Protein-2 as a Prognostic Marker in Patients with Ovarian Cancer
In ovarian cancer IGFBP-2 is elevated at diagnosis, and corresponds to stage and histology with patients in the highest tertile more likely to relapse and have a poorer outlook, and IGF BP-2 may be an important additional prognostic marker in this disease.


Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients.
It is concluded that IGFBP-2, which is the main IGFBP produced by prostate epithelial cells, is elevated in the serum of patients with prostate carcinoma, and that the degree of this elevation is related to serum prostate-specific antigen levels and the stage of the tumor.
Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.
It is suggested that IGFBPs may be involved in growth modulation of prostate malignancy and that alterations in their serum levels may serve as a marker for prostate cancer.
Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells.
Data indicate that prostate carcinoma cells secrete specific IGFBPs, as well as a general IGFBP protease, cathepsin D, in the proper environment, which is capable of hydrolyzing all endogenous IGFBP and modifying IGF-I action in prostatic cells.
Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.
It is speculated that PSA may serve to modulate IGF function within the reproductive system or in prostate cancer by altering IGF-IGFBP-3 interactions.
Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours.
The production of insulin-like growth factor I (IGF-I) and IGF-I binding proteins (BPs) by human lung tumour cell lines in vitro has been examined and the levels of these substances in the serum of
Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia.
Investigating whether IGFBP-2 levels in cerebrospinal fluid and serum could be useful markers for the diagnosis and follow-up of certain tumor types concluded that IGF BP-2 in CSF could be a specific marker for malignant CNS tumors.
Insulin‐like growth‐factor‐binding protein gene expression and protein production by human tumour cell lines
Findings indicate that the expression of multiple BP genes and the secretion of BPs may be a common property of tumour cells.
Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia.
It is concluded that the failure of serum IGFBP-3 and tumor IGF-II to complex with ALS is a primary cause of hypoglycemia in nonislet cell tumor hypoglyCEmia.
Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects.
It is suggested that plasma IGF BP-2 levels are more stable than IGFBP-1, and therefore IGFBP -2 may serve as a larger reservior that is available for IGF transport.
The IGF axis in the prostate.
  • P. Cohen, D. Peehl, R. Rosenfeld
  • Biology, Medicine
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 1994
The human prostate is demonstrated to contain all the elements of a functional IGF system and prostate specific antigen (PSA), secreted from PC- and found in seminal plasma, can function as a potent IGFBP-3 protease.